日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile

纳他珠单抗生物类似药与其参考药物的免疫原性比较评估:匹配的免疫原性谱

Chamberlain, Paul; Hemmer, Bernhard; Höfler, Josef; Wessels, Hendrik; von Richter, Oliver; Hornuss, Cyrill; Poetzl, Johann; Roth, Karsten

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial

拟开发的生物类似药那他珠单抗(PB006)在复发缓解型多发性硬化症患者中的疗效和安全性:羚羊3期随机临床试验

Hemmer, Bernhard; Wiendl, Heinz; Roth, Karsten; Wessels, Hendrik; Höfler, Josef; Hornuss, Cyrill; Liedert, Bernd; Selmaj, Krzysztof

Pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects

在健康受试者中评估培非格司亭生物类似药Pelmeg®的药效学、安全性和免疫原性

Wessels, Hendrik; Lehnick, Dirk; Höfler, Josef; Jankowsky, Ruediger; Chamberlain, Paul; Roth, Karsten

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects.

在健康受试者中,Pelmeg®(一种培非格司亭生物类似药)的药代动力学、药效学、安全性和免疫原性

Roth Karsten, Lehnick Dirk, Wessels Hendrik, Höfler Josef, Gastl Barbara, Jankowsky Ruediger

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Blinatumomab 用于治疗成人 B 细胞前体急性淋巴细胞白血病微小残留病灶

Gökbuget, Nicola; Dombret, Hervé; Bonifacio, Massimiliano; Reichle, Albrecht; Graux, Carlos; Faul, Christoph; Diedrich, Helmut; Topp, Max S; Brüggemann, Monika; Horst, Heinz-August; Havelange, Violaine; Stieglmaier, Julia; Wessels, Hendrik; Haddad, Vincent; Benjamin, Jonathan E; Zugmaier, Gerhard; Nagorsen, Dirk; Bargou, Ralf C